We did not observe any significant correlation between expression of these markers and other clinicopathological features of patients including sex, lymph node metastasis, or tumor stage; however, the majority of EGFR/MSI1 overexpressed cases did not have any metastatic lymph nodes, were in tumor stage I/II, and were observed in males (5/7, 71.4%). The gene discussed is MSI1; the disease is neoplasm.